Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mentor 1: rFXIII in Congenital Factor XIII Deficiency
NCT00713648Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2008
- Primary completion
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of catridecacog, sponsored by Novo Nordisk. Primary endpoint: Rate of Bleeding Episodes Requiring Treatment With a FXIII Containing Product at 322 days. Started Aug 2008; status: completed.
02
Drugs
catridecacog
Beyond the preview
Go deeper on NCT00713648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00713648.